Myopia Profile

Essilor® Stellest® 2.0 lenses

Essilor® Stellest® 2.0 lenses† are spectacle lenses for myopia control, an evolution of the original Essilor® Stellest®‡ lenses which were the first FDA-market authorized spectacle lenses clinically proven to slow down myopia progression in children.1 Powered by H.A.L.T.* MAX technology, Essilor® Stellest® 2.0 lenses† incorporate lenslets with increased power and asphericity to generate a greater depth of volume of non-focused light compared to the first generation Essilor® Stellest® lenses.‡ Data from a one-year randomized contralateral crossover trial demonstrated greater myopia control efficacy with spectacle lenses powered by H.A.L.T.* MAX technology, with eye growth in myopic children being 1.88 times slower than with spectacle lenses powered by H.A.L.T.* technology. §2 Essilor® Stellest® 2.0 lenses† are Essilor®’s most efficacious spectacle lenses for myopia management .¶2

Essilor®, Stellest®, AIRWEAR® are trademarks of Essilor International.

* H.A.L.T. is an acronym for Highly Aspherical Lenslet Target and does not imply a “halt” or “stop” of myopia progression.

† Essilor® Stellest® 2.0 lenses are not currently available in all countries, including the U.S. and have not been cleared by the U.S. FDA. 

‡ Essilor® Stellest® lens regulatory status and product availability may vary by country. U.S. FDA authorization and indications for use are based solely on clinical trial data from the U.S.

§ Based on 12-month results from a prospective, randomized, double-masked contralateral crossover clinical trial conducted in Singapore on 50 myopic children. The estimated cumulative 12-month axial length change (eye growth) was 0.228 mm with Essilor® Stellest® lenses and 0.121 mm with Essilor® Stellest® 2.0 lenses. The 1.88× ratio reflects the relative difference between these values (1 / [0.121 / 0.228] = 1.88).

Compared to products within the Essilor® portfolio

1. FDA. FDA Authorizes Marketing of First Eyeglass Lenses to Slow Progression of Pediatric Myopia. FDA News Release. 2025 Sept 25.

2. Raveendran RN, et al. Effect of increased power and asphericity of highly aspherical lenslets on myopia control efficacy: a contralateral crossover study. Transl Vis Sci Technol. 2025;14(11):9. doi:10.1167/tvst.14.11.9

Visit the Essilor® Stellest® 2.0 lenses website.

Spectacle lenses
EssilorLuxottica
Essilor® Stellest® 2.0 lenses
Spectacle lenses for myopia correction and control with Highly Aspherical Lenslet Target (H.A.L.T.*) MAX technology
Spectacle lenses with H.A.L.T.* MAX technology comprise a spherical front surface with 11 concentric rings formed by contiguous aspherical lenslets. Each lenslet does not have a single focal power, instead generating a volume of non-focused light in front of the retina, as a slow-down signal for eye growth. Compared with Essilor® Stellest® lenses powered by H.A.L.T.* technology, H.A.L.T.* MAX technology generates approximately twice the depth of volume of non-focused light, positioned further in front of the retina and spread over a wider area. The central area of the lens without lenslets provides distance vision correction.
AIRWEAR® polycarbonate
With full refraction, taking monocular pupillary distances and monocular heights.
 Platinum Sponsor Spectacles

Articles on Essilor® Stellest® 2.0.

Introducing Essilor® Stellest® 2.0 lenses - Q&A with Dr. Björn DrobeWe talk to Dr Björn Drobe about the research behind the Essilor® Stellest® 2.0 lens.‡ Read Full Article Boosted asphericity improves efficacy of Essilor Stellest designH.A.L.T. MAX lenses with increased lenslet asphericity slowed eye growth by 0.107 mm more than standard Stellest lenses over 12 months.Read Full Article Understanding the current evidence for myopia control methodsA 2026 overview of research on childhood myopia control, including optical, pharmacological and behavioural approaches shown to slow eye growth.Read Full Article
Introducing Essilor® Stellest® 2.0 lenses - Q&A with Dr. Björn DrobeWe talk to Dr Björn Drobe about the research behind the Essilor® Stellest® 2.0 lens.‡ Read Full Article

EssilorLuxottica resources

Bjorn Drobe.png

Essilor® Stellest® 2.0 lenses: Clinical Evidence

In this expert interview, Björn Drobe, Director of Applied Myopia Research at EssilorLuxottica, discusses the scientific rationale and clinical evidence behind Essilor® Stellest® 2.0 lenses. The video highlights the optical design principles, key findings from the published one-year clinical study, and what these results mean for myopia management in children. This interview can also be viewed on Leonardo, the EssilorLuxottica learning ecosystem.

Watch video